查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1933846

內視鏡減重市場依治療類型、產品類型、手術環境和最終用戶分類，全球預測（2026-2032）

Endoscopic Weight Loss Therapy Market by Therapy Type, Product Type, Procedure Setting, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年內視鏡減重治療市場價值為 3.1758 億美元，預計到 2026 年將成長至 3.5803 億美元，預計到 2032 年將達到 6.5074 億美元，複合年成長率為 10.79%。

關鍵市場統計數據
基準年 2025 3.1758億美元
預計年份：2026年 3.5803億美元
預測年份 2032 6.5074億美元
複合年成長率 (%) 10.79%

將當代內視鏡減重治療定位為一種微創選擇，從而重塑臨床路徑和相關人員的優先事項。

內視鏡減重方法已從實驗性技術發展成為系統性的臨床路徑，融合了胃腸病學、減重手術和門診手術等多個領域。新興技術將肥胖視為一種可透過微創內視鏡干預治療的疾病，治療方案也從純粹的外科手術轉向強調降低併發症風險、加快康復速度以及在臨床適宜的情況下可重複治療的內視鏡手術。這一發展趨勢正迫使包括醫療設備製造商、支付方和多學科醫療團隊在內的眾多相關人員重新評估臨床診療流程和病患選擇標準。

了解近年來在器械創新、治療路徑整合和實證醫學證據生成方面發生的變革性變化，這些變化促成了內視鏡肥胖治療的廣泛應用。

內視鏡減重領域正經歷著變革性的轉變，這主要得益於設備平台的創新、臨床實踐模式的演變以及跨學科合作的加強。製造商不斷改進縫合、釘合、吸引和胃內系統，以提高安全性，同時簡化使用者介面，促進更廣泛的應用。這使得學習曲線更短，門診和日間手術中心的應用率更高，並支持了更多臨床醫生參與，而不僅限於專科三級醫療機構。

分析2025年美國關稅調整將如何重塑內視鏡供應鏈中的設備採購、定價動態與籌資策略。

美國在2025年前實施的關稅措施和貿易政策調整，為依賴全球醫療設備供應鏈的供應商和醫療機構帶來了新的營運挑戰。某些進口零件關稅的提高可能會影響內視鏡系統的成本結構，尤其是在專用工具和精密耗材採購自國際製造地的情況下。這使得醫療機構和採購團隊面臨更大的壓力，需要重新評估供應商契約，協商長期協議，並考慮除單位成本之外的總到岸成本的影響。

詳細的細分分析揭示了治療亞型、產品分類和臨床環境如何共同影響臨床應用和商業化策略。

按治療方法類型分類的市場細分突顯了真空輔助、內視鏡袖狀胃成形術和胃內球囊治療各自不同的臨床作用和技術要求。以AspireAssist平台等系統為代表的真空輔助手術強調持久的引流介面和病患自主管理通訊協定，其所需的訓練和追蹤與醫師操作的手術有所不同。內視鏡袖狀胃成形術分為縫合系統和吻合器系統，每種系統在器械易用性、資金投入需求和臨床學習曲線方面均有所不同，這會影響胃腸病學家和減肥手術團隊的採納決策。胃內球囊進一步分為長期使用和短期使用，長期使用的器械強調持續放置和可回收設計，而短期球囊治療則側重於暫時性容量替代，手術複雜度較低。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和應用促進因素將影響部署、報銷和擴大策略。

區域趨勢顯著影響內視鏡減重療法在醫療保健系統中的推廣、報銷和普及。在美洲，成熟的臨床網路和相對較高的肥胖盛行率為早期應用奠定了基礎，加之支付方對經濟高效、微創治療方法的日益關注，使得該療法得以迅速普及。該地區的醫療機構正在門診項目中增加試點項目，並將相關設備整合到多學科體重管理流程中，從而加快臨床醫生技能的提升和患者的轉診。

競爭動態、夥伴關係以及以證據為導向的商業策略將決定哪些公司主導市場採用並維持長期的市場地位。

內視鏡減重治療產業的格局是由競爭與合作並存的動態所塑造。領先的設備開發人員致力於提升手術安全性、簡化使用者介面，並透過研究者主導的臨床試驗和註冊研究來拓展實證醫學證據基礎。同時，設備供應商與臨床網路之間的策略聯盟加速了培訓計畫的發展，擴大了早期採用者試點機構的覆蓋範圍，並促成了可操作數據的收集，從而為與支付方的溝通提供依據。併購仍是領先企業獲取差異化技術、建構涵蓋耗材、資本設備和數位化病人參與工具等全面產品組合的有效途徑。

整合臨床證據、訓練、供應鏈韌性和支付方參與，以促進內視鏡減重手術廣泛應用的實用策略建議

產業領導者應採取協作策略，整合臨床證據產生、支付方參與和營運部署，以加速內視鏡減重療法的合理推廣。首先，應優先進行前瞻性、真實世界研究和多中心註冊研究，以收集持續的患者療效和醫療成本指標。可靠的療效數據將顯著增強醫保報銷談判的力度，並提升臨床醫師的信心。其次，應投資於可擴展的臨床醫生培訓項目，結合實踐模擬、指導和數位化技能開發，以減少操作差異，並縮短不同醫療機構的推廣應用曲線。

嚴謹的混合方法整合了臨床醫生訪談、監管審查和三角驗證的證據，以得出檢驗的研究結果和局限性。

本調查方法結合了質性研究和系統性的二手研究，以確保結論的全面性和檢驗。質性研究包括對臨床醫生、醫院採購人員、門診手術經理和醫療設備製造商高階主管進行結構化訪談，並輔以與多學科諮詢委員會的討論。這些工作為了解手術流程、培訓需求、報銷談判和採購決策標準提供了背景資訊。訪談涵蓋了不同的地理和醫療機構類型，以收集多元化的營運觀點。

摘要強調，協調的證據、報銷的協調以及運作準備是內視鏡治療永續推廣的先決條件。

總之，內視鏡減重療法正處於一個關鍵的轉折點，其發展受到技術改進、實證醫學證據日趨成熟以及醫療服務經濟模式變化的影響。設備人體工學的改進、可操作性結果研究的開展以及培訓基礎設施的完善，共同提高了該療法在專科三級醫療中心之外推廣應用的可能性。然而，要實現常規臨床應用，則取決於實證醫學證據的產生、支付方的合作以及供應鏈的韌性等方面的協調行動。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 內視鏡減重減重市場（依治療方法）

  • 吸痰療法
  • 內視鏡袖狀胃成形術
    • 裝訂系統
    • 縫合系統
  • 胃內球囊
    • 長期氣球
    • 短期氣球

9. 依產品類型分類的內視鏡減重減重市場

  • 可重複使用的氣球
  • 免洗氣球

第10章 依治療環境分類的內視鏡減重減重市場

  • 住院治療
  • 門診

第11章 按最終用戶分類的內視鏡減重治療市場

  • 門診手術中心
    • 獨立中心
    • 醫院附設中心
  • 診所
    • 肥胖治療診所
    • 胃腸病診所
  • 醫院
    • 大學醫院
    • 社區醫院
  • 減重中心
    • 多學科合作中心
    • 單一治療中心

第12章 各地區內視鏡減重減重市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 內視鏡減重市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國內鏡減重治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

15. 美國內視鏡減重治療市場

第16章 中國內視鏡減重治療市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Allurion Technologies, Inc.
  • Apollo Endosurgery, Inc.
  • Aspire Bariatrics, Inc.
  • Bariatric Solutions GmbH
  • Bariatric Solutions International
  • BDB Limited
  • Boston Scientific Corporation
  • ConMed Corporation
  • Cousin Biotech
  • Districlass Medical
  • Endalis
  • Fractyl Health
  • GI Dynamics, Inc.
  • Helioscopie Medical Implants
  • Intuitive Surgical
  • Johnson & Johnson
  • Lexel Medical
  • MEDSIL
  • Medtronic plc
  • Obalon Therapeutics, Inc.
  • Olympus Corporation
  • ReShape Lifesciences, LLC
  • Silimed
  • Spatz FGIA
  • Spatz Medical Ltd.
  • USGI Medical, Inc.
  • WL Gore & Associates
Product Code: MRR-C36616F6997C

The Endoscopic Weight Loss Therapy Market was valued at USD 317.58 million in 2025 and is projected to grow to USD 358.03 million in 2026, with a CAGR of 10.79%, reaching USD 650.74 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 317.58 million
Estimated Year [2026] USD 358.03 million
Forecast Year [2032] USD 650.74 million
CAGR (%) 10.79%

Framing the modern trajectory of endoscopic weight loss interventions as minimally invasive options that reshape clinical pathways and stakeholder priorities

Endoscopic approaches to weight loss have matured from experimental techniques into structured clinical pathways that intersect gastroenterology, bariatrics, and ambulatory surgery. Emerging technologies now treat obesity as a condition amenable to minimally invasive endoluminal interventions, shifting care away from purely surgical solutions toward procedures that emphasize lower morbidity, quicker recovery, and repeatability when clinically appropriate. This evolution has invited a broader set of stakeholders-including device manufacturers, payers, and multidisciplinary care teams-to reassess clinical algorithms and patient selection criteria.

Clinicians increasingly view endoscopic therapies as complementary to lifestyle and pharmacologic interventions rather than as standalone endpoints. Consequently, iterative improvements in device design, procedural workflows, and post-procedure support models have focused attention on long-term patient engagement and outcome tracking. At the same time, regulatory pathways and reimbursement conversations have adapted to accommodate the growing evidence base, which in turn influences capital allocation and adoption pacing across care settings.

As we examine the landscape further, it becomes clear that the convergence of clinical need, technological refinement, and shifting provider economics has created an inflection point. Strategic stakeholders must therefore align clinical evidence generation, payer engagement, and commercialization strategies to realize the full potential of endoscopic weight loss therapies within contemporary care delivery models.

Understanding the recent transformative shifts in device innovation, care pathway integration, and evidence generation that enable broader adoption of endoscopic obesity interventions

The landscape of endoscopic weight loss therapy has experienced transformative shifts driven by innovation in device platforms, evolving clinical practice patterns, and strengthened interdisciplinary collaboration. Manufacturers have invested in iterative improvements across suturing, stapling, aspiration, and intragastric systems to enhance safety profiles while simplifying user interfaces for wider adoption. As a result, procedural learning curves have shortened, which facilitates diffusion into outpatient and ambulatory surgical settings and supports broader clinician participation beyond specialized tertiary centers.

Meanwhile, the integration of endoscopic therapies with structured weight management programs has shifted emphasis toward longitudinal care models. This movement encourages the deployment of digital health tools for patient engagement, remote monitoring, and outcomes assessment, thereby reinforcing the role of endoscopic therapies within comprehensive obesity management pathways. Additionally, regulatory clarity in several jurisdictions has allowed manufacturers and providers to pursue robust post-market evidence generation and pragmatic clinical studies that better reflect real-world practice.

Taken together, these shifts reduce barriers to clinical adoption and create new commercial pathways. Forward-looking stakeholders will therefore prioritize interoperability with care pathways, evidence-based reimbursement strategies, and partnerships that expand procedure accessibility across diverse clinical settings.

Analyzing how 2025 United States tariff adjustments reshape device sourcing, pricing dynamics, and procurement strategies across the endoscopic therapy supply chain

Recent tariff actions and trade policy adjustments within the United States for 2025 have introduced a new layer of operational complexity for suppliers and providers who rely on global medical device supply chains. Increased duties on select imported components can affect cost structures for endoscopic systems, particularly where specialized tooling and precision consumables are sourced from international manufacturing hubs. Accordingly, providers and procurement teams face heightened pressure to reassess supplier agreements, negotiate longer-term contracts, and examine total landed cost implications beyond unit price.

In response, manufacturers are exploring mitigation strategies that include supplier diversification, qualification of alternate component sources, and selective relocation of discrete manufacturing steps closer to major demand markets. These actions aim to insulate product availability and reduce exposure to tariff volatility. At the same time, some organizations will likely absorb incremental costs temporarily to maintain competitive pricing and market access, while others may implement measured price adjustments or revise service and consumable pricing models.

Importantly, increased tariffs intersect with reimbursement negotiations and capital purchasing cycles; providers must therefore anticipate procurement timing and evaluate the fiscal impact on capital acquisition decisions for new endoscopic platforms. In sum, trade policy changes in 2025 compel both vendors and healthcare purchasers to adopt more resilient sourcing strategies and proactive commercial planning to sustain supply continuity and predictable cost dynamics.

Detailed segmentation insights revealing how therapy subtypes, product classifications, and care settings collectively influence clinical adoption and commercialization strategies

Segmentation of the market by therapy type highlights distinct clinical roles and technological demands across aspiration therapy, endoscopic sleeve gastroplasty, and intragastric balloon solutions. Aspiration therapy, exemplified by systems like the AspireAssist platform, prioritizes durable drainage interfaces and patient-managed protocols that require different training and follow-up compared with operator-delivered procedures. Endoscopic sleeve gastroplasty divides into stapling systems and suturing systems, each introducing divergent device ergonomics, capital requirements, and clinical learning curves that influence adoption by gastroenterologists and bariatric teams. Intragastric balloons further bifurcate into long-term and short-term balloons; long-term devices emphasize sustained occupancy and retrievable designs while short-term balloons focus on temporary volume displacement with lower procedural complexity.

When viewed through the product-type lens, the market differentiates between reusable balloons and single-use balloons, a distinction that drives procurement preferences, sterilization workflows, and per-procedure cost calculus for facilities. Reusable platforms necessitate validated reprocessing capabilities and capital amortization, whereas single-use options sidestep reprocessing but require consistent supply reliability. From the end-user perspective, the procedure landscape spans ambulatory surgical centers, clinics, hospitals, and dedicated weight loss centers. Ambulatory surgical centers comprise freestanding sites and hospital-affiliated centers, clinics include bariatric and gastroenterology clinics, hospitals range from academic medical centers to community hospitals, and weight loss centers encompass multidisciplinary hubs and single-practice facilities. Finally, procedure setting segmentation into inpatient and outpatient care pathways shapes resource allocation, perioperative protocols, and patient throughput models.

Taken together, these segmentation dimensions inform product development priorities, clinical training programs, and commercialization strategies tailored to the operational realities of different provider types and procedure environments.

Regional dynamics and adoption drivers across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape deployment, reimbursement, and scaling strategies

Regional dynamics substantially influence how endoscopic weight loss therapies are introduced, reimbursed, and scaled across healthcare systems. In the Americas, established clinical networks and a relatively high prevalence of obesity have created fertile ground for early adoption, accompanied by growing payer interest in cost-effective, minimally invasive options. Providers in this region increasingly pilot outpatient programs and integrate devices into multidisciplinary weight management pathways, thereby accelerating clinician familiarity and patient referral flows.

Europe, Middle East & Africa display heterogeneous adoption patterns rooted in national reimbursement frameworks, variable procedural capacity, and differing regulatory timelines. Western European countries with clear reimbursement pathways tend to lead in technology uptake, while emerging markets within the region explore targeted deployment that aligns with local infrastructural capacities and specialist availability. The Middle East has shown interest in concentrated center-based programs, and parts of Africa focus on pilot initiatives tied to specialized centers.

In Asia-Pacific, rapid urbanization, expanding private healthcare sectors, and high unmet clinical need are driving interest in scalable endoscopic interventions. However, adoption varies with regulatory maturity and the availability of trained endoscopists. Cross-regionally, manufacturers must adapt market entry strategies to local payer structures and procedural workflows, and they must invest in clinician training and post-market evidence generation appropriate for each regulatory and reimbursement environment.

How competitive dynamics, partnerships, and evidence-focused commercial strategies determine which companies lead adoption and sustain long-term market presence

Competitive and collaborative forces define the company landscape supporting endoscopic weight loss therapy. Leading device developers concentrate on enhancing procedural safety, simplifying user interfaces, and broadening the evidence base through investigator-initiated studies and registries. At the same time, strategic partnerships between device suppliers and clinical networks have accelerated training programs, expanded access to early adopter sites, and enabled pragmatic data collection to inform payer conversations. Mergers and acquisitions remain a viable pathway for larger firms to acquire differentiated technologies and to build comprehensive portfolios that span consumables, capital equipment, and digital patient engagement tools.

Investors and corporate development teams evaluate companies based on technological differentiation, intellectual property protection, and the ability to execute robust post-market clinical programs. Meanwhile, smaller innovators often pursue niche strategies that target specific clinical indications or ergonomic improvements to win share within specialist practices. Importantly, supply chain reliability and regulatory compliance have become core competitive factors as providers demand predictable consumable availability and clear evidence of device lifecycle management. Overall, market participants that align clinical evidence generation with pragmatic commercialization and supply strategies position themselves favorably for sustained penetration across multiple care settings.

Actionable strategic recommendations for aligning clinical evidence, training, supply resilience, and payer engagement to drive scalable adoption of endoscopic obesity therapies

Industry leaders should adopt a coordinated strategy that aligns clinical evidence generation, payer engagement, and operational deployment to accelerate responsible adoption of endoscopic weight loss therapies. First, prioritize prospective real-world studies and multicenter registries that capture durable patient outcomes and cost-of-care metrics, because robust outcome data materially strengthen reimbursement discussions and clinician confidence. Second, invest in scalable clinician training programs that combine hands-on simulation, proctoring, and digital upskilling to reduce variability in procedural performance and to shorten adoption curves across diverse practice settings.

Concurrently, optimize supply chain resilience by qualifying multiple component sources, exploring regional manufacturing partnerships, and planning inventory buffers that reduce exposure to trade-related disruptions. Firms should also design flexible pricing and service models that consider differences between reusable and single-use products, as well as the distinct procurement priorities of ambulatory surgical centers versus hospitals. Finally, engage payers early with value dossiers that clearly articulate patient selection criteria, downstream cost implications, and real-world outcomes. By synchronizing evidence, training, supply operations, and payer narratives, organizations can create sustainable pathways to scale while maintaining high standards of patient safety and clinical effectiveness.

Rigorous mixed-method research approach integrating clinician interviews, regulatory review, and triangulated evidence to produce validated insights and limitations

The research methodology combines primary qualitative insight with systematic secondary analysis to ensure comprehensive, validated conclusions. Primary research involved structured interviews with clinicians, hospital procurement leaders, ambulatory surgery administrators, and device executives, supplemented by advisory board discussions with multidisciplinary specialists. These engagements provided context on procedure workflows, training needs, reimbursement conversations, and procurement decision criteria. Interviews were conducted across varied geographies and provider types to capture diverse operational perspectives.

Secondary research encompassed regulatory documents, peer-reviewed clinical literature, device instructions for use, and policy publications. Data triangulation occurred by cross-referencing interview inputs with published evidence and regulatory guidance to reduce bias and to validate emerging themes. Analytical techniques included thematic coding of qualitative inputs, comparative assessment of device features and procedural workflows, and scenario analysis for supply chain and policy impacts. The methodology also accounted for limitations, including variability in regional reimbursement landscapes and the evolving nature of long-term clinical outcome data. Ethical considerations and confidentiality agreements governed all primary interviews and data handling to protect participant anonymity and proprietary information.

Concluding synthesis that emphasizes coordinated evidence, reimbursement alignment, and operational readiness as prerequisites for sustainable adoption of endoscopic therapies

In conclusion, endoscopic weight loss therapy stands at a pivotal juncture shaped by technological refinement, evidence maturation, and changing care delivery economics. The cumulative effect of improved device ergonomics, pragmatic outcome studies, and expanded training infrastructures has increased the feasibility of broadening procedural access beyond specialized tertiary centers. Yet, the pathway to routine clinical integration hinges on coordinated action across evidence generation, payer engagement, and supply chain resilience.

Looking ahead, stakeholders who proactively align clinical development with reimbursement strategies and who invest in scalable training and post-procedure care models will most effectively translate innovation into routine practice. Trade policy shifts and regional heterogeneity in reimbursement require adaptive commercialization plans and localized value propositions. Ultimately, the successful diffusion of endoscopic obesity interventions will depend on demonstrable patient benefit, clear economic rationale for payers, and operational models that deliver reliable, high-quality care across diverse clinical settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Endoscopic Weight Loss Therapy Market, by Therapy Type

  • 8.1. Aspiration Therapy
  • 8.2. Endoscopic Sleeve Gastroplasty
    • 8.2.1. Stapling Systems
    • 8.2.2. Suturing Systems
  • 8.3. Intragastric Balloon
    • 8.3.1. Long-Term Balloons
    • 8.3.2. Short-Term Balloons

9. Endoscopic Weight Loss Therapy Market, by Product Type

  • 9.1. Reusable Balloons
  • 9.2. Single-Use Balloons

10. Endoscopic Weight Loss Therapy Market, by Procedure Setting

  • 10.1. Inpatient
  • 10.2. Outpatient

11. Endoscopic Weight Loss Therapy Market, by End User

  • 11.1. Ambulatory Surgical Centers
    • 11.1.1. Freestanding Centers
    • 11.1.2. Hospital Affiliated Centers
  • 11.2. Clinics
    • 11.2.1. Bariatric Clinics
    • 11.2.2. Gastroenterology Clinics
  • 11.3. Hospitals
    • 11.3.1. Academic Hospitals
    • 11.3.2. Community Hospitals
  • 11.4. Weight Loss Centers
    • 11.4.1. Multidisciplinary Centers
    • 11.4.2. Single Practice Centers

12. Endoscopic Weight Loss Therapy Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Endoscopic Weight Loss Therapy Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Endoscopic Weight Loss Therapy Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Endoscopic Weight Loss Therapy Market

16. China Endoscopic Weight Loss Therapy Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Allurion Technologies, Inc.
  • 17.6. Apollo Endosurgery, Inc.
  • 17.7. Aspire Bariatrics, Inc.
  • 17.8. Bariatric Solutions GmbH
  • 17.9. Bariatric Solutions International
  • 17.10. BDB Limited
  • 17.11. Boston Scientific Corporation
  • 17.12. ConMed Corporation
  • 17.13. Cousin Biotech
  • 17.14. Districlass Medical
  • 17.15. Endalis
  • 17.16. Fractyl Health
  • 17.17. GI Dynamics, Inc.
  • 17.18. Helioscopie Medical Implants
  • 17.19. Intuitive Surgical
  • 17.20. Johnson & Johnson
  • 17.21. Lexel Medical
  • 17.22. MEDSIL
  • 17.23. Medtronic plc
  • 17.24. Obalon Therapeutics, Inc.
  • 17.25. Olympus Corporation
  • 17.26. ReShape Lifesciences, LLC
  • 17.27. Silimed
  • 17.28. Spatz FGIA
  • 17.29. Spatz Medical Ltd.
  • 17.30. USGI Medical, Inc.
  • 17.31. W. L. Gore & Associates

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PROCEDURE SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ASPIRATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ASPIRATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ASPIRATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY STAPLING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY STAPLING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY STAPLING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY SUTURING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY SUTURING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY SUTURING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INTRAGASTRIC BALLOON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INTRAGASTRIC BALLOON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INTRAGASTRIC BALLOON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY LONG-TERM BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY LONG-TERM BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY LONG-TERM BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY SHORT-TERM BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY SHORT-TERM BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY SHORT-TERM BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY REUSABLE BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY REUSABLE BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY REUSABLE BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY SINGLE-USE BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY SINGLE-USE BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY SINGLE-USE BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PROCEDURE SETTING, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY FREESTANDING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY FREESTANDING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY FREESTANDING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITAL AFFILIATED CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITAL AFFILIATED CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITAL AFFILIATED CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY BARIATRIC CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY BARIATRIC CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY BARIATRIC CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY GASTROENTEROLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY GASTROENTEROLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY GASTROENTEROLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ACADEMIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ACADEMIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ACADEMIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY COMMUNITY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY COMMUNITY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY COMMUNITY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY WEIGHT LOSS CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY WEIGHT LOSS CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY WEIGHT LOSS CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY WEIGHT LOSS CENTERS, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY MULTIDISCIPLINARY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY MULTIDISCIPLINARY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY MULTIDISCIPLINARY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY SINGLE PRACTICE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY SINGLE PRACTICE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY SINGLE PRACTICE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PROCEDURE SETTING, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY WEIGHT LOSS CENTERS, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PROCEDURE SETTING, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY WEIGHT LOSS CENTERS, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PROCEDURE SETTING, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY WEIGHT LOSS CENTERS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PROCEDURE SETTING, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY WEIGHT LOSS CENTERS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PROCEDURE SETTING, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY WEIGHT LOSS CENTERS, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PROCEDURE SETTING, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY WEIGHT LOSS CENTERS, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PROCEDURE SETTING, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY WEIGHT LOSS CENTERS, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PROCEDURE SETTING, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY WEIGHT LOSS CENTERS, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PROCEDURE SETTING, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY WEIGHT LOSS CENTERS, 2018-2032 (USD MILLION)
  • TABLE 182. GCC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GCC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. GCC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, 2018-2032 (USD MILLION)
  • TABLE 185. GCC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 186. GCC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. GCC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PROCEDURE SETTING, 2018-2032 (USD MILLION)
  • TABLE 188. GCC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. GCC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 190. GCC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 191. GCC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 192. GCC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY WEIGHT LOSS CENTERS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PROCEDURE SETTING, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY WEIGHT LOSS CENTERS, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PROCEDURE SETTING, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY WEIGHT LOSS CENTERS, 2018-2032 (USD MILLION)
  • TABLE 215. G7 ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. G7 ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. G7 ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, 2018-2032 (USD MILLION)
  • TABLE 218. G7 ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 219. G7 ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. G7 ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PROCEDURE SETTING, 2018-2032 (USD MILLION)
  • TABLE 221. G7 ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. G7 ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 223. G7 ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 224. G7 ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 225. G7 ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY WEIGHT LOSS CENTERS, 2018-2032 (USD MILLION)
  • TABLE 226. NATO ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. NATO ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. NATO ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, 2018-2032 (USD MILLION)
  • TABLE 229. NATO ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 230. NATO ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. NATO ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PROCEDURE SETTING, 2018-2032 (USD MILLION)
  • TABLE 232. NATO ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. NATO ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 234. NATO ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 235. NATO ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 236. NATO ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY WEIGHT LOSS CENTERS, 2018-2032 (USD MILLION)
  • TABLE 237. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PROCEDURE SETTING, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY WEIGHT LOSS CENTERS, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PROCEDURE SETTING, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY WEIGHT LOSS CENTERS, 2018-2032 (USD MILLION)